The role of endothelin receptor antagonists in cardiovascular pharmacotherapy

Bibliography

• YANAGISAWA M, KURIHARA H, KIMURA S, et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 332:411–415.
   PubMed Web of Science ®Google Scholar
• ••First description and pharmacological characterisation ofET.
   Google Scholar
• RUBANYI GM, POLOKOFF MA: Endothelins: molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol Rev. (1994) 46:325–415.
   PubMed Web of Science ®Google Scholar
• •Somewhat outdated, but still by far the most comprehensive review.
   Google Scholar
• LeSCHER TF, BARTON M: Endothelins and endothelin receptor antagonists. Circulation (2000) 102:2434–2440.
   PubMed Web of Science ®Google Scholar
• BURKE SE, NELSON RA, LUBBERS NL, et al.: Evidence for vasoconstriction mediated by the endothelin-B receptor in domestic swine. J. Cardiovasc. Pharmacol (2000) 35:838–844.
   PubMed Web of Science ®Google Scholar
• DUPUIS J, GORESKY CA, FOURNIER A: Pulmonary clearance of circulating endothelin-1 in dogs in viva exclusive role of ETB receptors. J Appl Physic]. (1996) 81:1510–1515.
   PubMed Web of Science ®Google Scholar
• DUPUIS J, STEWART DJ, CERNACEK P, GOSSELIN G: Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation (1996) 94:1578–1584.
   PubMed Web of Science ®Google Scholar
• DUPUIS J, SCHWAB AJ, SIMARD A, et al.: Kinetics of endothelin-1 binding in the dog liver microcirculation in vivo. Am. J. Physiol. (1999) 277:G905–G914.
   PubMed Web of Science ®Google Scholar
• STRACHAN FE, SPRATT JC, WILKINSON IB, et al.: Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension (1999) 33:581–585.
   PubMed Web of Science ®Google Scholar
• OZAKI S, OHWAKI K, ISHIKAWA K, YANO M: Coexpres-sion studies with endothelin receptor subtypes indicate the existence of intracellular cross-talk between ETA and ETB receptors. J Biochem. (1997) 121:440–447.
   PubMed Web of Science ®Google Scholar
• VERHAAR MC, STRACHAN FE, NEWBY DE, et al.: Endothelin-A receptor antagonist mediated vasodila-tation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation (1998) 97:752–756.
   PubMed Web of Science ®Google Scholar
• MURAMATSU M, OKA M, MORIO Y et al.: Chronic hypoxia augments endothelin-B receptor-mediated vasodilation in isolated perfused rat lungs. Am. J Physiol. (1999) 276:L358–L364.
   PubMed Web of Science ®Google Scholar
• BOBIK A, GROOMS A, MILLAR JA, MITCHELL A, GRINPUKEL S: Growth factor activity of endothelin on vascular smooth muscle. Am. J. Physiol. (1990) 258:C408–C415.
   PubMed Web of Science ®Google Scholar
• MATSUMURA Y, KURO T, KOBAYASHI Y et al.: Exagger-ated vascular and renal pathology in endothelin-B receptor-deficient rats with deoxycorticosterone acetate-salt hypertension. Circulation (2001) 102:2765–2773.
   Web of Science ®Google Scholar
• HONING MLH, HIJMERING ML, BALLARD DE, et al.: Selective ETA receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans. J. Am. Soc. Nephrol. (2000) 11:1498–1504.
   PubMed Web of Science ®Google Scholar
• MOREAU P: Endothelin in hypertension: a role for receptor antagonists Cardiovasc. Res. (1998) 39:534–542.
   Google Scholar
• •Well written review covering the field extensively.
   Google Scholar
• SCHIFFRIN EL: Role of endothelin-1 in hypertension. Hypertension (1999) 34:876–881.
   PubMed Web of Science ®Google Scholar
• SCHIFFRIN EL, TURGEON A, DENG LY: Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hyperten-sion in rats. Br. J. Pharmacol. (1997) 121:935–940.
   PubMed Web of Science ®Google Scholar
• ROHMEISS P, BIRCK R, BRAUN C, et al.: Pharmacology of the endothelinA receptor antagonist: LU 135252. Cardiovasc. Drug Rev. (1999) 16:391–412.
   Google Scholar
• LARIVIERE R, THIBAULT G, SCHIFFRIN EL: Increased endothelin-1 content in blood vessels of deoxycorti-costerone acetate-salt hypertensive but not in sponta-neously hypertensive rats. Hypertension (1993) 21:294–300.
   PubMed Web of Science ®Google Scholar
• ERGUL S, PARISH DC, PUETT D, ERGUL A: Racial differ-ences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension (1996) 28:652–655.
   PubMed Web of Science ®Google Scholar
• ELIJOVICH F, LAFFER CL, AMADOR E, et al.: Regulation of plasma endothelin by salt in salt-sensitive hyperten-sion. Circulation (2001) 103:263–268.
   PubMed Web of Science ®Google Scholar
• KRUM H, VISKOPER RJ, LACOURCIERE Y et al.: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hyperten-sion. N Eng]. J. Med. (1998) 338:784–790.
   PubMed Web of Science ®Google Scholar
• ••First and (up to now) only clinical paper on ET receptorantagonism in hypertension.
   Google Scholar
• CLOZEL M, BREU V, GRAY GA, et al: Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Therap. (1994) 270:228–235.
   PubMed Web of Science ®Google Scholar
• CALHOUN DA, RENFROE K, ALPER AB: Oral sitaxsentan and endothelin-a selective receptor antagonist, reduces systemic blood pressure in patients with mild-to-moderate primary hypertension. Circulation (2000) 102:11-417 (2029).
   Google Scholar
• MYLONA P, CLELAND JGF: Update of REACH-1 and MERIT-HF clinical trials in heart failure. Eur. J. Heart Fail. (1999) 1:197–200.
   PubMed Web of Science ®Google Scholar
• DONCKIER JE, MASSART P-E, HODEIGE D, et al.: Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition. Circulation (1997) 96:1250–1256.
   PubMedGoogle Scholar
• TEERLINK JR, LOFFLER B-M, HESS P, et al.: Role ofendothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Circulation (1994) 90:2510–2518.
   PubMed Web of Science ®Google Scholar
• MONTER K, EHMKE H, KIRCHENGAST M: Maintenance of blood pressure in normotensive dogs by endothelin-1. Am. J. Physic)]. (1999) 276:H1022–H1027.
   Google Scholar
• SOTSCH G, KIOWSKI W, YAN Y-W et al.: Short-term oral endothelin-receptor antagonist therapy in conven-tionally treated patients with sympatomatic severe chronic heart failure. Circulation (1998) 98:2262–2268.
   PubMed Web of Science ®Google Scholar
• CLAVELL AL, STINGO AJ, MARGULIES KB, et al.: Physio-logical significance of endothelin. Its role in conges-tive heart failure. Circulation (1993) 87:V45–V50.
   Google Scholar
• HUNTINGTON K, PICARD P, MOE GW, et al.: Increasedcardiac and pulmonary endothelin-1 mRNA expres-sion in canine induced heart failure. J. Cardiovasc. Pharmacol. (1998) 31:S424–S426.
   PubMed Web of Science ®Google Scholar
• WEI CM, LERMAN A, RODEHEFFER RJ, et al.: En do th elin inhuman congestive heart failure. Circulation (1994) 89:1580–1586.
   PubMed Web of Science ®Google Scholar
• OMLAND T, LIE RT, AAKVAAG A, AARSLAND T, DICKSTEIN K: Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation (1994) 89:1573–1579.
   PubMed Web of Science ®Google Scholar
• MULDER P, RICHARD V, BOUCHART F, et al.: Selective ETAreceptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure. Cardiovasc. Res. (1998) 39:600–608.
   PubMed Web of Science ®Google Scholar
• MOE GW, ALBERNAZ A, NAIK GO, KIRCHENGAST M, STEWART DJ: Beneficial hemodynamic effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure. Cardio-vasc. Res. (1998) 39:571–579.
   PubMed Web of Science ®Google Scholar
• SAKAI S, MIYAUCHI T, KOBAYASHI M, et al.: Inhibition ofmyocardial endothelin pathway improves long-term survival in heart failure. Nature (1996) 384:353–355.
   PubMed Web of Science ®Google Scholar
• SHIMOYAMA H, SABBAH HN, BORZAK S, et al.: Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure. Circulation (1996) 94:779–784.
   PubMed Web of Science ®Google Scholar
• WADA A, TSUTAMOTO T, FUKAI D, et al.: Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure. JACC (1997) 30:1385–1392.
   Google Scholar
• BORGESON DD, GRANTHAM AJ, WILLIAMSON EE, et al.:Chronic oral endothelin Type A receptor antagonism in experimental heart failure. Hypertension (1998) 31:766–770.
   PubMed Web of Science ®Google Scholar
• KIRCHENGAST M, MONTER K: Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. Proc. Soc. Exp. Biol. Med. (1999) 221: 312–325.
   Google Scholar
• ••Comprehensive review discussing, not only heart failure,but also vascular hypertrophy and restenosis.
   Google Scholar
• KIOWSKI W, SOTSCH G, HUNZIKER P, et al: Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet (1995) 346:732–736.
   PubMed Web of Science ®Google Scholar
• •First clinical paper describing acute haemodynamic effects of a non-selective ETRA in CHF.
   Google Scholar
• SPIEKER LE, MITROVIC V, NOLL G, et al.: Acute hemody- namic and neurohumoral effects of selective ETA receptor blockade in patients with congestive heart failure. JACC (2000) 35:1745–1752.
   Google Scholar
• •First clinical paper describing acute haemodynamic effects of a selective ETA receptor antagonist in CHF.
   Google Scholar
• GIVERTZ MM, COLLUCI WS, LEJEMTEL TH, et al: Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation (2000) 101:2922–2927.
   PubMed Web of Science ®Google Scholar
• SeTSCH G, BERTEL 0, KIOWSKI W: Acute and short term effects of the non-peptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc. Drugs Ther. (1997) 10:717–725.
   PubMed Web of Science ®Google Scholar
• RUSCHITZKA FT,PACHER R, ENSELEIT F, et al.: Chronic selective ETA receptor blockade in congestive heart failure. The heat trial (Heart failure ETA receptor blockade trial). Circulation (2000) 102:11-593 (2876).
   Google Scholar
• PACKER M, CASPI A,CHARLON V, et al.: Multicenter, double-blind, placebo controlled study of long-term endothelin blockade with bosentan in chronic heart failure- Results of the REACH-1 trial. Circulation (1998) 98:1-3 (12).
   Google Scholar
• MICHAEL JR, MARKEWITZ BA: En do th elin s and the lung. Am. J. Respir. Crit. Care Med. (1996) 154:555–581.
   PubMed Web of Science ®Google Scholar
• ••Very informative paper discussing all possible effects of ETin the lung, including pulmonary hypertension.
   Google Scholar
• DUPUIS J: Endothelin receptor antagonists and their developing role in cardiovascular therapeutics. Can. J Cardiol. (2000) 16:903–910.
   PubMed Web of Science ®Google Scholar
• PRIE. S, KI LEUNG T, CERNACEK P, RYAN JW, DUPUIS J: The orally active ETA receptor antagonist (+)-(8)-2 -(4,6 -dime th ox y -pyrimidin -2 - yloxy)-3-methoxy-3,3-diphenyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. J. Pharmacol. Exp. Therap. (1997) 282:1312–1318.
   PubMed Web of Science ®Google Scholar
• PRIE. S, DUPUIS J: The ETA receptor antagonist LU 135252 prevents the progression of established pulmonary hypertension induced by monocrotaline in rats. J. Cardiovasc. Pharmacol. Therap. (1999) 4:1–8.
   PubMedGoogle Scholar
• NGUYEN QT, COLOMBO F, ROULEAU JL, DUPUIS J, CALDERONE A: LU 135252, an endothelinA receptor antagonist did not prevent pulmonary vascular remodelling or lung fibrosis in a rat model of myocar-dial infarction. Br. J. Pharmacol (2000) 130:1525–1530.
   PubMed Web of Science ®Google Scholar
• WILLIAMSON DJ, WALLMAN LL, JONES R, et al.: Hemody-namic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation (2000) 1 02 :411–418.
   Google Scholar
• CHANNICK RN, RUBIN LISIMMONEAU G, et al.: Bosentan, a dual endothelin receptor antagonist, improves exercise capacity and hemodynamics in patients with pulmonary arterial hypertension: results of a double blind, randomized, placebo-controlled trial. Circula-tion (2000) 102:11-100 (476).
   Google Scholar
• BARST MICH S, HORN EM, et al.: Efficacy and safety of chronic treatment with the oral selective endothelin-A receptor blocker sitaxsentan in pulmonary arterial hypertension. Circulation (2000) 102:11-427 (2076).
   PubMedGoogle Scholar
• The sixth report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. Arch. Intern. Med. (1997) 157(20:2413–2446.
   PubMedGoogle Scholar
• BARTON M, HAUDENSCHILD CC, D'USCIO LV, et al.:Endothelin blockade inhibits atherosclerosis and restores endothelial function. Proc. Nati Acad. Sci. (1998) 95:14367–14372.
   PubMed Web of Science ®Google Scholar
• ROHMEISS P, BIRCK R, BRAUN C, KIRCHENGAST M, VANDER WOUDE FJ: Targets for endothelin in the diseased kidney: Clues for therapeutic intervention. Exp. Nephrol. (1999) 7:1–10.
   PubMedGoogle Scholar
• •For readers interested in renal disease.
   Google Scholar
• BENIGNI A: Endothelin antagonists in renal disease. Kidney Int. (2000) 57:1778–1794.
   PubMed Web of Science ®Google Scholar
• KURIHARA Y, KURIHARA H, SUZUKI H, et al.: Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature (1994) 368:703–710.
   PubMed Web of Science ®Google Scholar
• TREINEN KA, LOUDEN C, DENNIS MJ, WIER PJ: Develop-mental toxicity and toxicokinetics of two endothelin receptor antagonists in rats and rabbits. Teratology (1999) 59:51–59.
   PubMedGoogle Scholar